187 related articles for article (PubMed ID: 14529407)
1. CB 1954: from the Walker tumor to NQO2 and VDEPT.
Knox RJ; Burke PJ; Chen S; Kerr DJ
Curr Pharm Des; 2003; 9(26):2091-104. PubMed ID: 14529407
[TBL] [Abstract][Full Text] [Related]
2. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.
Knox RJ; Jenkins TC; Hobbs SM; Chen S; Melton RG; Burke PJ
Cancer Res; 2000 Aug; 60(15):4179-86. PubMed ID: 10945627
[TBL] [Abstract][Full Text] [Related]
3. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).
Knox RJ; Friedlos F; Boland MP
Cancer Metastasis Rev; 1993 Jun; 12(2):195-212. PubMed ID: 8375021
[TBL] [Abstract][Full Text] [Related]
4. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide).
Boland MP; Knox RJ; Roberts JJ
Biochem Pharmacol; 1991 Mar 15-Apr 1; 41(6-7):867-75. PubMed ID: 1901207
[TBL] [Abstract][Full Text] [Related]
5. Phthalimide analogs of CB 1954: synthesis and bioactivation.
Mehta LK; Hobbs S; Chen S; Knox RJ; Parrick J
Anticancer Drugs; 1999 Sep; 10(8):777-83. PubMed ID: 10573210
[TBL] [Abstract][Full Text] [Related]
6. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.
Knox RJ; Friedlos F; Jarman M; Roberts JJ
Biochem Pharmacol; 1988 Dec; 37(24):4661-9. PubMed ID: 3202902
[TBL] [Abstract][Full Text] [Related]
7. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase.
Anlezark GM; Melton RG; Sherwood RF; Wilson WR; Denny WA; Palmer BD; Knox RJ; Friedlos F; Williams A
Biochem Pharmacol; 1995 Aug; 50(5):609-18. PubMed ID: 7669063
[TBL] [Abstract][Full Text] [Related]
8. Aerobic nitroreduction by flavoproteins: enzyme structure, mechanisms and role in cancer chemotherapy.
Skelly JV; Knox RJ; Jenkins TC
Mini Rev Med Chem; 2001 Sep; 1(3):293-306. PubMed ID: 12369976
[TBL] [Abstract][Full Text] [Related]
9. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2).
Knox RJ; Boland MP; Friedlos F; Coles B; Southan C; Roberts JJ
Biochem Pharmacol; 1988 Dec; 37(24):4671-7. PubMed ID: 3144286
[TBL] [Abstract][Full Text] [Related]
10. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase.
Wu K; Knox R; Sun XZ; Joseph P; Jaiswal AK; Zhang D; Deng PS; Chen S
Arch Biochem Biophys; 1997 Nov; 347(2):221-8. PubMed ID: 9367528
[TBL] [Abstract][Full Text] [Related]
11. Caffeine, aminoimidazolecarboxamide and dicoumarol, inhibitors of NAD(P)H dehydrogenase (quinone) (DT diaphorase), prevent both the cytotoxicity and DNA interstrand crosslinking produced by 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) in Walker cells.
Roberts JJ; Marchbank T; Kotsaki-Kovatsi VP; Boland MP; Friedlos F; Knox RJ
Biochem Pharmacol; 1989 Nov; 38(22):4137-43. PubMed ID: 2480794
[TBL] [Abstract][Full Text] [Related]
12. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
Helsby NA; Atwell GJ; Yang S; Palmer BD; Anderson RF; Pullen SM; Ferry DM; Hogg A; Wilson WR; Denny WA
J Med Chem; 2004 Jun; 47(12):3295-307. PubMed ID: 15163209
[TBL] [Abstract][Full Text] [Related]
13. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase.
Knox RJ; Friedlos F; Sherwood RF; Melton RG; Anlezark GM
Biochem Pharmacol; 1992 Dec; 44(12):2297-301. PubMed ID: 1472095
[TBL] [Abstract][Full Text] [Related]
14. Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT).
Knox RJ; Friedlos F; Jarman M; Davies LC; Goddard P; Anlezark GM; Melton RG; Sherwood RF
Biochem Pharmacol; 1995 May; 49(11):1641-7. PubMed ID: 7786305
[TBL] [Abstract][Full Text] [Related]
15. Nitroreductase-based GDEPT.
Denny WA
Curr Pharm Des; 2002; 8(15):1349-61. PubMed ID: 12052212
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model.
Wu K; Eng E; Knox R; Chen S
Arch Biochem Biophys; 2001 Jan; 385(1):203-8. PubMed ID: 11361019
[TBL] [Abstract][Full Text] [Related]
17. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
Weedon SJ; Green NK; McNeish IA; Gilligan MG; Mautner V; Wrighton CJ; Mountain A; Young LS; Kerr DJ; Searle PF
Int J Cancer; 2000 Jun; 86(6):848-54. PubMed ID: 10842200
[TBL] [Abstract][Full Text] [Related]
18. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.
Helsby NA; Ferry DM; Patterson AV; Pullen SM; Wilson WR
Br J Cancer; 2004 Mar; 90(5):1084-92. PubMed ID: 14997211
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
Green NK; Youngs DJ; Neoptolemos JP; Friedlos F; Knox RJ; Springer CJ; Anlezark GM; Michael NP; Melton RG; Ford MJ; Young LS; Kerr DJ; Searle PF
Cancer Gene Ther; 1997; 4(4):229-38. PubMed ID: 9253508
[TBL] [Abstract][Full Text] [Related]
20. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs.
Celli CM; Tran N; Knox R; Jaiswal AK
Biochem Pharmacol; 2006 Jul; 72(3):366-76. PubMed ID: 16765324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]